50 results on '"Diaz-Rubio, E."'
Search Results
2. P-99 Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials
3. Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project
4. Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study
5. The quality oncology practice initiative program: Experience in Spain
6. PCN118 - THE BURDEN OF CANCER IN SPAIN
7. Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay
8. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project
9. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database
10. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
11. Benefits of upfront primary tumour resection (UPTR) according to sidedness in mCRC: Retrospective analyses of TTD MACRO-2 and PLANET randomised trials
12. First prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis
13. Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group
14. Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISNÚ Program
15. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
16. How do Spanish medical oncologists manage breakthrough pain? A national study
17. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
18. 2122 Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial
19. 2033 Stage III colorectal cancer (CRC) in Spain: A retrospective analysis from 35 centres
20. Erlotinib (ERL) versus Pemetrexed (MTA) as Second-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): Efficacy and Safety Data
21. Differences in Kras and Braf Mutation Prevalence in Metastatic Colorectal Carcinoma Using High-Sensitivity Taqmelt vs Arms-Scorpion Pcr Assays
22. Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients
23. 6004 ORAL Role of Baseline Circulating Tumour Cells and KRas Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemotherapy Plus Bevacizumab: a TTD Spanish Group Cooperative Study
24. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
25. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
26. 285 PROGNOSTIC VALUE OF QUANTIFYING CIRCULATING TUMOURAL CELLS (CTC), CIRCULATING ENDOTHELIAL CELLS (CEC) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN HORMONE SENSITIVE METASTATIC PROSTATE CANCER
27. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
28. 902 CIRCULATING TUMOR CELLS (CTC) IN THE THREE TUMOR TYPES OF EPITHELIAL ORIGIN: PROSTATE, BREAST AND COLORECTAL, IN PATIENTS WITH AND WITHOUT METASTASIS
29. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007
30. 1LB 5-year overall survival update from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant treatment for stage-III colon cancer
31. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006
32. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005
33. What have we learned and where are we going in the treatment of colorectal and gastric cancer?
34. 303 Capecitabine plus oxaliplatin (XELOX): findings from a human colon cancer xenograft model and a phase II clinical trial in patients with metastatic colorectal cancer (MCRC)
35. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group
36. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
37. Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure
38. Cost-effectiveness of interferon for high-risk (stage III) melanoma patients
39. Gastrointestinal Tract Cancer Liaison Office: An attempt to organise clinical research in Europe
40. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study
41. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
42. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
43. 738 Oxaliplatin (L-OHP®): Summary of results in advanced colorectal cancer (ACC)
44. Gastroesophageal reflux in patients with nonobstructive dysphagia
45. Clinical and manometric findings in patients with chronic belching
46. Meningeal and brain metastases in primary malignant pericardial mesothelioma
47. Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone
48. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer
49. Emesis during past pregnancy: A new prognostic factor in chemotherapy-induced emesis
50. Cis-platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC gastrointestinal tract cancer cooperative group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.